HC Wainwright reissued their buy rating on shares of Aclaris Therapeutics (NASDAQ:ACRS – Free Report) in a research note published on Wednesday morning,Benzinga reports. HC Wainwright currently has a $16.00 price objective on the biotechnology company’s stock. HC Wainwright also issued estimates for Aclaris Therapeutics’ FY2026 earnings at ($0.61) EPS, Q1 2027 earnings at ($0.13) EPS, Q2 2027 earnings at ($0.12) EPS, Q3 2027 earnings at ($0.14) EPS, Q4 2027 earnings at ($0.16) EPS and FY2027 earnings at ($0.55) EPS.
A number of other brokerages have also recently commented on ACRS. Weiss Ratings reissued a “sell (d-)” rating on shares of Aclaris Therapeutics in a research report on Monday, September 21st. Canaccord Genuity Group began coverage on Aclaris Therapeutics in a research note on Tuesday, September 1st. They issued a “buy” rating and a $10.00 price target on the stock. Finally, Wall Street Zen raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, October 24th. Three equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Aclaris Therapeutics currently has an average rating of “Buy” and an average target price of $11.00.
Read Our Latest Stock Report on Aclaris Therapeutics
Aclaris Therapeutics Price Performance
Shares of NASDAQ ACRS opened at $3.97 on Wednesday. Aclaris Therapeutics has a 1 year low of $2.10 and a 1 year high of $6.60. The firm has a 50-day moving average of $4.88 and a 200 day moving average of $4.52.
Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.01. The business had revenue of $1.63 million for the quarter, compared to analyst estimates of $1.38 million. Aclaris Therapeutics had a negative net margin of 921.50% and a negative return on equity of 61.65%. On average, equities analysts forecast that Aclaris Therapeutics will post -0.62 EPS for the current year.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Aclaris Therapeutics in the 3rd quarter worth $40,000. Profund Advisors LLC raised its stake in shares of Aclaris Therapeutics by 462.3% in the third quarter. Profund Advisors LLC now owns 171,421 shares of the biotechnology company’s stock worth $902,000 after purchasing an additional 140,935 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Aclaris Therapeutics by 20.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 26,858 shares of the biotechnology company’s stock worth $142,000 after purchasing an additional 4,630 shares during the last quarter. MBE Wealth Management LLC purchased a new position in shares of Aclaris Therapeutics in the third quarter worth $53,000. Finally, Braidwell LP lifted its holdings in shares of Aclaris Therapeutics by 26.1% during the second quarter. Braidwell LP now owns 2,142,348 shares of the biotechnology company’s stock valued at $11,333,000 after purchasing an additional 443,232 shares in the last quarter. 98.34% of the stock is owned by hedge funds and other institutional investors.
More Aclaris Therapeutics News
Here are the key news stories impacting Aclaris Therapeutics this week:
- Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $0.61 from $0.62 and its FY2027 estimate to a loss of $0.55 from $0.60. The firm also improved its quarterly 2027 forecasts, reflecting expectations for somewhat lower losses. HC Wainwright maintained a Buy rating and a $16 price target, substantially above ACRS’s recent trading level. HC Wainwright analyst estimates
- Positive Sentiment: HC Wainwright separately reaffirmed its Buy rating, reinforcing the analyst’s constructive view of Aclaris’s pipeline and longer-term prospects. HC Wainwright Reaffirms Buy Rating for Aclaris Therapeutics
- Neutral Sentiment: Aclaris discussed ATI-052 proof-of-concept results in atopic dermatitis and asthma. The update highlights ongoing pipeline development, but the available report does not provide enough detail to assess the results’ likely commercial or regulatory impact. Aclaris ATI-052 proof-of-concept results
- Negative Sentiment: Wedbush issued a pessimistic forecast for ACRS’s stock price, creating a counterweight to HC Wainwright’s bullish outlook and potentially contributing to weaker investor sentiment. Wedbush Issues Pessimistic Forecast for Aclaris Therapeutics
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company focused on developing therapies for immune-inflammatory diseases. The company’s research programs are designed to address conditions in areas such as rheumatology, dermatology and other inflammatory disorders.
Aclaris’ lead investigational product is zunsemetinib (ATI-450), an oral small-molecule therapy being evaluated for inflammatory diseases. The company has also developed additional investigational programs, including selective kinase inhibitors intended for potential use in dermatologic and immune-mediated conditions.
See Also
- Five stocks we like better than Aclaris Therapeutics
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
